Join us for a free webinar on Monday, 7 June at 05:00 PM CEST about the results of the TIGER trial evaluating the safety and effectiveness of Tigertriever in restoring blood flow by removing clots in patients with AIS-LVO.
The webinar will be moderated by Dr. Jan-Hendrik Buhk, Germany. Speakers of the webinar are:
- Ashutosh Jadhav, MD, Barrow Neurological Institute
- Brian Jankowitz, MD, Cooper University Health Care
The webinar is supported by Rapid Medical and registration for the webinar is free.
What is the webinar about?
Results of the TIGER trial evaluating the safety and effectiveness of Tigertriever in restoring blood flow by removing clots in patients with AIS-LVO.
The Tigertriever is a highly effective and safe device to remove thrombus in LVO stroke patients eligible for mechanical thrombectomy.
- Tigertriever achieved high reperfusion rate in LVO patients:
- 63.2% mTICI 2c-3 within 3 passes of the Tigertriever
- 84.6% mTICI 2b-3 within 3 passes (Primary Endpoint)
- 95.7% mTICI 2b-3 final procedural revascularization
- High one-pass success:
- 57.8% mTICI 2b-3 successful first-pass reperfusion
- 41.4% mTICI 2c-3 excellent first-pass reperfusion
- Good clinical and safety outcomes:
- Functional independence (mRS 0-2) in 58%
- Nondisabled (mRS 0-1) in 47.3%
- SICH in 1.7%; Mortality 90d in 18.1%
About the speaker & moderator
The moderator of the webinar is Dr. Jan-Hendrik Buhk, Germany.
The presenters of the webinar are:
- Ashutosh Jadhav, MD, PhD
He is a vascular and interventional neurologist at Barrow Neurological Institute. He is board certified in neurology and vascular neurology by the American Board of Psychiatry and Neurology. He also holds a certification in neurocritical care from the United Council of Neurologic Subspecialties and in neuroendovascular surgery from the Society of Neurological Surgeons Committee on Advanced Subspecialty Training.Dr. Jadhav’s expertise includes the medical and endovascular care of patients who have had a stroke. He is a member of the American Academy of Neurology, the American Stroke Association, the European Stroke Organisation, the Society for Neurointerventional Surgery, the Society of Vascular and Interventional Neurology, and the World Stroke Organization.
Dr. Jadhav earned his PhD in genetics from Harvard University and his medical degree from the Harvard-MIT Program in Health Sciences and Technology in Boston. He completed his neurology residency at Brigham and Women’s Hospital and Massachusetts General Hospital in Boston. He completed his fellowship in vascular neurology and interventional neuroradiology at University of Pittsburgh Medical Center.Dr. Jadhav’s research interests include treatment approaches and patient outcomes after a stroke due to large-vessel occlusion, workflow optimization in the acute stroke population, and equipment development.
- Brian Jankowitz, MD
World-class vascular neurosurgeon Brian Jankowitz, MD, recently joined Cooper University Health Care as Director of the Cerebrovascular Program at the Cooper Neurological Institute. Dr. Jankowitz brings extensive training, knowledge, and skills to the Cooper Neurological Institute, one of the few, truly multi-disciplinary cerebrovascular teams in the region, consisting of specialists in neurology, neurosurgery, and neuroradiology.Prior to joining Cooper, Dr. Jankowitz was associate professor of neurological surgery at the University of Pittsburgh School of Medicine and served as faculty of the UPMC Neurosurgery Department and UPMC Stroke Institute, where he specialized in both open and endovascular neurosurgery.Dr. Jankowitz earned a bachelor of science degree from the University of Notre Dame and received his medical degree from Temple University School of Medicine. He then completed his surgical internship, neurosurgical residency, and fellowship in cerebrovascular surgery at the University of Pittsburgh Medical Center. He is board certified in neurological surgery and CAST (Committee on Advanced Subspeciality Training) in neuroendovascular surgery. He is the primary investigator for numerous clinical trials in the United States, which will available to patients at Cooper.
What to expect?
The ESMINT webinar provides you the opportunity to meet experts, who share with you their experience, practice, and way of thinking regarding everyday challenges in the field of neurointerventions.
The webinar will be an interactive live transmission. All participants will be able to ask questions through a live online chat.